Balyasny Asset Management
EVLO

Balyasny Asset Management’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Balyasny Asset Management’s Portfolio EVLO Stock Details EVLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-507
Closed -$16.3K – 3334
2022
Q4 		$16.3K Buy
+507
New +$20.1K ﹤0.01% 2507

Other funds holding EVLO

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $170M AUM 34.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Balyasny Asset Management's EVLO Position: Q1 2023 in Review

Balyasny Asset Management sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q1 2023, closing a stake of 507 shares — an estimated $16.3K sold.

Balyasny Asset Management first reported a position in EVLO in Q4 2022 and held it in 1 quarter. The position peaked at $16.3K in Q4 2022. 39 funds tracked by Wall St. Rank hold EVLO as of Q1 2023.

  • Balyasny Asset Management reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Balyasny Asset Management sold 507 Evelo Biosciences, Inc. Common Stock shares in Q1 2023, an estimated $16.3K.
  • Balyasny Asset Management first reported a position in Evelo Biosciences, Inc. Common Stock in Q4 2022 and held it in 1 quarter.
  • Balyasny Asset Management's Evelo Biosciences, Inc. Common Stock position peaked at $16.3K in Q4 2022.
  • 39 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q1 2023.

Based on Balyasny Asset Management's 13F filing for Q1 2023, filed 15 May 2023.